Platelet-Rich Plasma Injection for Achilles Tendinopathy

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Achilles Tendinopathy+1 More
Platelet-Rich Plasma Injection - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will use real-time ultrasound to study the difference between healthy and unhealthy Achilles tendons, as well as the degree of healing after minimally invasive surgery and injections of Platelet-Rich Plasma.

Eligible Conditions
  • Achilles Tendinopathy

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Month 6, Month 9, Month 12

Month 6
Change in tendinopathy assessed by B mode sonographic imaging
Change in tendinopathy assessed by SWE
Month 12
Structure of achilles tendon

Trial Safety

Trial Design

1 Treatment Group

Platelet-Rich Plasma Injection
1 of 1
Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: Platelet-Rich Plasma Injection · No Placebo Group · N/A

Platelet-Rich Plasma Injection
Procedure
Experimental Group · 1 Intervention: Platelet-Rich Plasma Injection · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: month 6, month 9, month 12

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,501 Previous Clinical Trials
2,677,541 Total Patients Enrolled
Felix Gonzalez, MDPrincipal InvestigatorEmory University

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
will be screened for eligibility Patients with lower extremity pain will be screened for eligibility if they do not have Achilles tendon involvement.
You have a clinical diagnosis of achillodynia.
An ultrasound confirmed the diagnosis of tendinopathy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 13th, 2021

Last Reviewed: October 7th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.